Early pivotal trials demonstrating the efficacy of sorafenib for patients with advanced hepatocellular cancer included primarily those with minimal liver dysfunction (Child-Pugh [CP] class A). The current Phase 2 study examined sorafenib treatment in both CP class A and B patients. Those with CP class B liver dysfunction were shown to tolerate sorafenib but treatment outcomes remained less satisfactory than for CP class A patients.SOURCE:
Pressiani T, et al. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: A prospective feasibility analysis. Ann Oncol 2013;24:406-411.